In psoriatic arthritis, exhibiting different comorbidities may require different treatment regimens. In this installment of our monthly psoriatic arthritis quiz, we present a few different scenarios. How good are you at coming up with an effective treatment plan? Test your knowledge with this quiz.
David Ozeri, M.D.
A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.
Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.
In round two of our ongoing psoriatic arthritis quiz series, we focus on treatment recommendations made in the 2018 ACR/NPF psoriatic arthritis treatment guidelines. We also include a puzzler based on findings from a newly published study.
Increased mortality described in the first study to review all-cause mortality and cause-specific mortality in patients with psoriasis.
Doctors should be vigilant about recognizing the signs and symptoms of patients who may develop ILD in order to prevent catastrophic complications, such as respiratory failure.